South Korea's veterinary medicines authority has announced the formation of a working group on geroscience drug oversight, joining Japan as the second major Asia-Pacific market to formally engage with the topic at the regulatory level. The announcement is brief — a single bulletin item naming the working group's chair and confirming an initial mandate to publish a framework document within the next twelve months — but it ends the longstanding silence from the South Korean regulator on a question its industry has been quietly asking for at least two years.

The working group's composition signals what kind of framework is likely to emerge. The chair is a veterinary pharmacologist with extensive prior involvement in the country's recent reforms to companion-animal medicine oversight. The initial members include representatives from the major South Korean veterinary teaching hospitals, the Seoul-based pet insurance industry association, and one observer from each of the leading domestic veterinary pharmaceutical companies. Notably absent from the initial roster is direct representation from the international sponsors most likely to file in South Korea once the framework exists, which is consistent with how the regulator typically structures these working groups but does mean the international perspective will arrive through formal consultation rather than embedded participation.

South Korea has historically followed the lead of Japan and the EU on novel veterinary medicine oversight, with selective domestic modifications. The expected pattern here is similar: a framework that broadly mirrors whichever international approach proves most workable, with adjustments for the specific structure of the South Korean veterinary market — which is heavily concentrated in metropolitan Seoul, dominated by chain-affiliated practices, and characterized by unusually high ownership of small-breed dogs.

For South Korean owners, the practical implication is that the country is now formally on the regulatory map for canine longevity drugs. The realistic timeline for actual prescribing remains in line with the rest of the Asia-Pacific region — eighteen to thirty months behind whichever of the major Western markets approves first — but the existence of an active working group means South Korean owners can expect informed discussion in their own veterinary practices much sooner than the prescribing timeline would suggest.

We'll mirror the eventual framework document on the South Korea country page within seven days of publication.